The FDA has approved Dupixent for the treatment of children aged two to 11 years with chronic spontaneous urticaria who remain symptomatic despite histamine-1 antihistamine treatment. This expands the previous approval for Dupixent in adults and adolescents aged 12 years and older. The approval is based primarily on data from the LIBERTY-CUPID clinical study program.
Dupilumab is being jointly developed by Sanofi (SNY,SAN.PA) and Regeneron (REGN) under a global collaboration agreement. Dupixent is now approved for nine different allergy-related conditions, from asthma to atopic dermatitis. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in phase 3 studies.
At last close, shares of Sanofi were trading at 80.78 euros, down 0.30%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.